Axsome Therapeutics - AXSM Market Value
The price evolution of Axsome Therapeutics (AXSM) reflects the dynamics of a business focused on the expansion of innovative migraine and depression treatments in the US. The current figure is 7.40. Revenue stability is increasing due to steady demand for neurotherapy; however, high marketing costs, challenges in implementing new formulas, and pressure from insurance intermediaries threaten margins.
AXSM (Axsome Corp): analytical breakdowns and indicator data
- stock price and consensus target price:
- issuer market value details:
- book value of equity indicators:
- company liabilities and liquidity data:
Total Debt to Capital Axsome Therapeutics|AXSM - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Axsome Therapeutics|AXSM - Company Aggregate Debts|Debt to Book Capitalization Ratio Axsome Corp|AXSM - Company Long-Term Loans and Borrowings|Company Short-Term Debt Axsome Therapeutics|Quick Ratio axsome.com
- business earnings and investment ratios data:
AXSM - Net Profit|Future Profit Axsome Therapeutics|AXSM - Price to Earnings Multiple|Future Price to Earnings Axsome Therapeutics Inc|AXSM - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Axsome Corp|AXSM - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Axsome Therapeutics|AXSM - Net earnings per share for the last 12 months|Quarterly EPS earnings growth axsome.com|AXSM - Earnings per share growth rate in current year|Expected earnings per share growth for next year Axsome Therapeutics
Fundamental company analysis:AXSM (Axsome Therapeutics, Inc.)
Market capitalization measures the aggregate value of all the issuer's shares, reflecting the fundamental maturity of the business through the lens of market expectations. Analyzing the market's total valuation of Axsome Therapeutics (AXSM) allows for a correlation between the value of its assets and its strategy of repurposing known molecules, where the stability of this indicator confirms the effectiveness of bringing depression and migraine treatments to market.
Key competitors
Biogen - Market Valuation|NBIX: Market Capitalization|RGC - Market Value|Market Capitalization ACADIA Corp ACAD|Xenon Pharmaceuticals (XENE) - Market Value|Market Valuation vikingtherapeutics.com|Market Value Supernus|Market Capitalization CPRX (Catalyst Pharma)|Market Capitalization DNLI|HRMY - Market Value|Biohaven Ltd. - Market Valuation|Market Capitalization amylyx.com AMLX|TRVI - Market Value|Market Value PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Market Value|Market Value CeriBell EEG (CBLL)|PRTA (Prothena Corporation PLC) - Market Capitalization|Market Capitalization Alector Therapeutics|Market Valuation ANNX (Annexon)|omeros.com - Market Capitalization|Market Value Neurogene Corp NGNE|Market Capitalization AC Immune Inc (ACIU)|VYGR - Market Value|Market Value neumoratx.com|Scilex (SCLX) - Market Value|Market Valuation Tevogen Bio Holdings Inc.|ACOG (Alpha Cognition Inc) - Market Capitalization|Market Value cogrx.com CGTX|Market Valuation IKT (Inhibikase Therapeutics)|SAVA (cassavasciences.com) - Market Value|Assertio - Market Valuation|Market Value COYA (Coya Therapeutics Inc)|VistaGen Therapeutics Inc - Market Capitalization|Market Value OVID (Ovid Therapeutics Inc.)|ABOS: Market Capitalization|Market Value cervomed.com (CRVO)|Market Value Alterity Therapeutics Ltd.|CLNN: Market Value|Market Capitalization PEPG|Market Capitalization jupiterneurosciences.com (JUNS)|Market Value Relmada Therapeutics RLMD|ANVS (annovisbio.com) - Market Valuation|Grace Tx - Market Capitalization|Market Value Firefly Neuroscience, Inc.|KLTO (anewmeds.com) - Market Valuation|NeuroSense Therapeutics Ltd. (NRSN) - Market Capitalization|Market Valuation RVPH|MTVA (MetaVia, Inc.) - Market Value|Market Capitalization NRXS|Market Capitalization heliusmedical.com|Market Capitalization PASG (Passage Bio)|NEUP - Market Valuation|NERV - Market Value|Market Capitalization athira.com ATHA|ADXN: Market Capitalization|Alzamend Neuro (ALZN) - Market Capitalization|Market Valuation CYCN|Market Capitalization PTIX (Protagenic)|Market Value Pasithea Therapeutics (KTTA)|Market Capitalization cortigent.com|Market Value Avenue Therapeutics, Inc. ATXI|BCLI - Market Valuation|CARA - Market Value|CHRO (Chromocell) - Market Capitalization|ELYM: Market Capitalization|Market Value Intra-Cellular Therapies, Inc. (ITCI)|Market Valuation LBPH|Market Capitalization Marinus Pharmaceuticals Inc|Market Value NKGen (NKGN)|NRBO (NeuroBo Pharma) - Market Value|Market Value Sage Therapeutics, Inc. SAGE|synaptogen.com (SNPX) - Market Value|Trevena - Market Capitalization|VIGL - Market Capitalization|WENA (Anew Medical, Inc.) - Market Valuation|Market Capitalization CERE
